Skip to main content

Peer Review reports

From: Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study

Original Submission
2 Mar 2015 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
24 Jul 2015 Editorially accepted
5 Aug 2015 Article published 10.1186/s12913-015-0971-4

You can find further information about peer review here.

Back to article page